JP2017519019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519019A5 JP2017519019A5 JP2016574274A JP2016574274A JP2017519019A5 JP 2017519019 A5 JP2017519019 A5 JP 2017519019A5 JP 2016574274 A JP2016574274 A JP 2016574274A JP 2016574274 A JP2016574274 A JP 2016574274A JP 2017519019 A5 JP2017519019 A5 JP 2017519019A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- mdm2i
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 201000001441 melanoma Diseases 0.000 claims 3
- -1 5- chloro-1-methyl-2-oxo-1,2-dihydro - pyridine -3 -Yl Chemical class 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- CLRSLRWKONPSRQ-CPOWQTMSSA-N (1s)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)CC2CCC(CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-CPOWQTMSSA-N 0.000 claims 1
- KJCIMSSFGUGTGA-UHFFFAOYSA-N 1-methylpiperazin-2-one Chemical compound CN1CCNCC1=O KJCIMSSFGUGTGA-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- JLXZMLLNPNOODV-UHFFFAOYSA-N imidazol-4-one Chemical compound O=C1C=NC=N1 JLXZMLLNPNOODV-UHFFFAOYSA-N 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017406P | 2014-06-26 | 2014-06-26 | |
| US62/017,406 | 2014-06-26 | ||
| PCT/IB2015/054792 WO2015198266A1 (en) | 2014-06-26 | 2015-06-25 | Intermittent dosing of mdm2 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519019A JP2017519019A (ja) | 2017-07-13 |
| JP2017519019A5 true JP2017519019A5 (enExample) | 2018-08-09 |
| JP6728072B2 JP6728072B2 (ja) | 2020-07-22 |
Family
ID=53510950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574274A Expired - Fee Related JP6728072B2 (ja) | 2014-06-26 | 2015-06-25 | ｍｄｍ２阻害剤の間欠投与 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US20170196866A1 (enExample) |
| EP (1) | EP3160463B1 (enExample) |
| JP (1) | JP6728072B2 (enExample) |
| KR (3) | KR102462177B1 (enExample) |
| CN (2) | CN106456635A (enExample) |
| AU (1) | AU2015278765B2 (enExample) |
| BR (1) | BR112016029750A2 (enExample) |
| CA (1) | CA2953079C (enExample) |
| CL (1) | CL2016003295A1 (enExample) |
| ES (1) | ES2856210T3 (enExample) |
| IL (1) | IL249138B (enExample) |
| MX (1) | MX2016017075A (enExample) |
| PH (1) | PH12016502556A1 (enExample) |
| RU (1) | RU2695228C2 (enExample) |
| SG (1) | SG11201609853VA (enExample) |
| TN (1) | TN2016000522A1 (enExample) |
| TW (1) | TW201613576A (enExample) |
| WO (1) | WO2015198266A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN107106642B (zh) | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| RU2762573C2 (ru) | 2016-11-15 | 2021-12-21 | Новартис Аг | Доза и режим введения для ингибиторов взаимодействия hdm2 с p53 |
| KR20190129889A (ko) * | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
| JP7358372B2 (ja) * | 2018-03-12 | 2023-10-10 | 羅欣薬業（上海）有限公司 | イミダゾピロロン化合物及びその使用 |
| WO2019180576A1 (en) | 2018-03-20 | 2019-09-26 | Novartis Ag | Pharmaceutical combinations |
| IL308399B2 (en) * | 2018-04-30 | 2025-08-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| EP3801476A4 (en) * | 2018-05-25 | 2022-07-06 | Kartos Therapeutics, Inc. | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS |
| JP2022514280A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | Ｍｄｍ２阻害剤のための延長低用量レジメン |
| WO2021053489A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of an mdm2 inhibitor for the treatment of myelofibrosis |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| US20030139373A1 (en) | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
| AU2006216780B8 (en) | 2005-02-22 | 2010-04-22 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| UA108746C2 (xx) * | 2009-12-22 | 2015-06-10 | Заміщені ізохінолінони та хіназолінони | |
| PL2361667T3 (pl) | 2010-02-25 | 2015-07-31 | General Electric Technology Gmbh | Płuczka wodna i sposób oczyszczania gazu procesowego |
| CA2817585A1 (en) * | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| JP2014507384A (ja) * | 2010-12-16 | 2014-03-27 | ロシュ グリクアート アーゲー | Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法 |
| BR112014003113A2 (pt) | 2011-08-11 | 2017-03-14 | Estetra Sprl | método de contracepção de emergência em uma fêmea mamífero |
| US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
| JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
| US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| HUE045880T2 (hu) | 2012-07-31 | 2020-01-28 | Novartis Ag | A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| RS60142B1 (sr) | 2013-12-05 | 2020-05-29 | Hoffmann La Roche | Novi kombinovani tretman za akutnu mijeloidnu leukemiju (aml) |
| CA2931073C (en) | 2013-12-23 | 2021-10-26 | Novartis Ag | Pharmaceutical combinations |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| HK1249030A1 (zh) | 2015-02-06 | 2018-10-26 | Unity Biotechnology, Inc. | 化合物及在治疗衰老相关病症中的用途 |
| US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
| TWI804010B (zh) | 2015-08-03 | 2023-06-01 | 瑞士商諾華公司 | 作為血液學毒性生物標記之gdf-15 |
| WO2017037579A1 (en) | 2015-08-28 | 2017-03-09 | Novartis Ag | Mdm2 inhibitors and combinations thereof |
| RU2762573C2 (ru) | 2016-11-15 | 2021-12-21 | Новартис Аг | Доза и режим введения для ингибиторов взаимодействия hdm2 с p53 |
| CA3044501A1 (en) | 2016-11-22 | 2018-05-31 | Novartis Ag | Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof |
| WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
| KR20190129889A (ko) | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
| WO2019073435A1 (en) | 2017-10-12 | 2019-04-18 | Novartis Ag | COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS |
| WO2019180576A1 (en) | 2018-03-20 | 2019-09-26 | Novartis Ag | Pharmaceutical combinations |
| CA3115716A1 (en) | 2018-10-30 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Method of treatment of p53 wt tumors |
| JP2022514280A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | Ｍｄｍ２阻害剤のための延長低用量レジメン |
| CN113631558A (zh) | 2019-04-04 | 2021-11-09 | 诺华股份有限公司 | Siremadlin琥珀酸酯 |
-
2015
- 2015-06-24 TW TW104120384A patent/TW201613576A/zh unknown
- 2015-06-25 ES ES15733926T patent/ES2856210T3/es active Active
- 2015-06-25 CN CN201580034558.4A patent/CN106456635A/zh not_active Withdrawn
- 2015-06-25 SG SG11201609853VA patent/SG11201609853VA/en unknown
- 2015-06-25 WO PCT/IB2015/054792 patent/WO2015198266A1/en not_active Ceased
- 2015-06-25 EP EP15733926.8A patent/EP3160463B1/en active Active
- 2015-06-25 US US15/321,042 patent/US20170196866A1/en not_active Abandoned
- 2015-06-25 TN TN2016000522A patent/TN2016000522A1/en unknown
- 2015-06-25 AU AU2015278765A patent/AU2015278765B2/en not_active Ceased
- 2015-06-25 CA CA2953079A patent/CA2953079C/en active Active
- 2015-06-25 MX MX2016017075A patent/MX2016017075A/es unknown
- 2015-06-25 RU RU2017102319A patent/RU2695228C2/ru active
- 2015-06-25 CN CN202211129314.2A patent/CN115569197A/zh not_active Withdrawn
- 2015-06-25 KR KR1020167035797A patent/KR102462177B1/ko active Active
- 2015-06-25 KR KR1020247021711A patent/KR20240110659A/ko not_active Ceased
- 2015-06-25 JP JP2016574274A patent/JP6728072B2/ja not_active Expired - Fee Related
- 2015-06-25 KR KR1020227037821A patent/KR20220151027A/ko not_active Ceased
- 2015-06-25 BR BR112016029750A patent/BR112016029750A2/pt not_active Application Discontinuation
-
2016
- 2016-11-22 IL IL249138A patent/IL249138B/en active IP Right Grant
- 2016-12-20 PH PH12016502556A patent/PH12016502556A1/en unknown
- 2016-12-22 CL CL2016003295A patent/CL2016003295A1/es unknown
-
2017
- 2017-12-21 US US15/849,770 patent/US20180110779A1/en not_active Abandoned
-
2018
- 2018-12-17 US US16/221,650 patent/US20190209561A1/en not_active Abandoned
-
2020
- 2020-06-11 US US16/898,886 patent/US11419870B2/en active Active
-
2022
- 2022-07-25 US US17/814,599 patent/US20230092181A1/en not_active Abandoned
-
2024
- 2024-04-11 US US18/632,528 patent/US20240261284A1/en active Pending